• Tonix highlighted TONMYA’s U.S. launch for fibromyalgia, positioning it as the first new FDA-approved treatment in more than 15 years.
• Reported 1Q’26 net sales of USD 3.7 million; USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
• Commercial uptake metrics included more than 2,600 unique prescribers from Nov. 17, 2025 to Apr. 17, 2026.
• Cash and cash equivalents totaled about USD 185.5 million as of Mar. 31, 2026; no debt; runway expected into early Q2’27.
• Pipeline milestones include a planned adaptive Phase 2 Lyme disease prevention field study for TNX-4800 in 1H’27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.